Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Why did S&P 500 end three-day win streak? How did Trump's US-China rare earths deal impact markets? What caused rubber futures to plunge after BYD cuts? Why is JPMorgan CEO warning of economic deterioration? How are immigration raids affecting US businesses today? Why are Disney and Universal suing AI firm Midjourney? How is Tesla's delayed robotaxi launch affecting stock?

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

benzinga.com/analyst-stock-ratings/initiation/25/06/45866812/omeros-analyst-sees-1-billion-potential-for-narsoplimab-before-fda-decision

H.C. Wainwright analyst Brandon Folkes initiated coverage on Omeros Corporation (NASDAQ:OMER) with a Buy rating and a price forecast of $9.
According to Brandon, Omeros holds significant long-term value potential due to its expansive rare disease pipeline.
While the company has faced…

This story appeared on benzinga.com, 2025-06-10 16:53:07.